key: cord-0947274-a4uqoo3d
authors: Gupta, Mohit D.; Qamar, Arman; Mp, Girish; Safal, Safal; Batra, Vishal; Basia, Deepak; Mandal, Sunil K.; Yusuf, Jamal; Mukhopadhyay, Saibal; Bansal, Ankit
title: Bradyarrhythmias in patients with COVID-19: A case series
date: 2020-08-19
journal: Indian Pacing Electrophysiol J
DOI: 10.1016/j.ipej.2020.08.004
sha: 5c69f0741b65f2943bfc6780fc7d8b56f5af4192
doc_id: 947274
cord_uid: a4uqoo3d

Novel coronavirus disease (COVID-19) can have variety of cardiac manifestations; however, less is known about the prevalence, clinical characteristics and outcomes of bradyarrhythmias in patients with COVID-19. In the present case series of bradyarrhythmia in patients with COVID-19, we report complete heart block requiring intervention in 5 patients and sinus node dysfunction in 2 patients.

Abstract: Novel coronarvirus disease can have variety of cardiac manifestations; however, less is known about the prevalence, clinical characteristics and outcomes of bradyarrhythmias in patients with COVID-19. In the present case series of bradyarrhythmia in patients with COVID-19, we report complete heart block requiring intervention in 5 patients and sinus node dysfunction in 2 patients.

Several cardiovascular complications of Coronarvirus disease 2019 (COVID-19) including myocardial infarction, myocarditis, stroke, tachyarrhythmias and pulmonary embolism have been reported during the current pandemic. However, less is known about the prevalence, clinical characteristics and outcomes of bradyarrhythmias in patients with COVID-19. 1 We report a case series of 7 patients with COVID-19 who presented with bradyarrhythmias. Of them, 5 had complete heart block and 2 had sick sinus syndrome. The clinical characteristics of the patients are summarized in Table 1 The patients were aged between 45-80 years. Out of these 3 were women. 2 patients had prior history of diabetes mellitus, hypertension, or myocardial infarction and 1 had a history of heart failure. None of the patients were on calcium channel blockers, beta-blockers, digoxin or anti-arrhythmic drugs at baseline. In addition, hydroxychloroquine, azithromycin, zinc, remdesivir or convalescent plasma was not given of any of the patients for treatment of COVID-19.

All of the seven patients presented within 24-48 hours of symptom onset. Of these, 5 presented with recent onset syncope and 2 with presyncope. However, only 2 patients had history of fever. All patients were hemodynamically stable and none had hypoxia. Laboratory invasive test for myocarditis is currently unavailable at our medical centre due to the COVID-19 pandemic. However, since only 1 patient in our case series had an elevated high-sensitive troponin T, a marker of myocardial injury, we expect that the majority of these patients did not have myocarditis.

In conclusion, patients with COVID-19 may be observed for possible bradyarrhythmias.

While, there is no definitive evidence of causality. 

The Variety of Cardiovascular Presentations of COVID-19

Novel coronavirus 19 (COVID-19) associated sinus node dysfunction: a case series

Transient complete heart block in a patient with critical COVID-19

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic

SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS